This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Durata Therapeutics, Inc. Reports Full-Year 2012 Financial Results

CHICAGO, March 8, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the year ended December 31, 2012.

"2012 was a great year for Durata. We accomplished many things from a clinical, regulatory and organizational perspective that position us well for a successful 2013 and beyond," said Paul Edick, Chief Executive Officer of Durata Therapeutics, Inc. "Our financial results reflect our increase in spending as we were concluding our studies and preparing for submission to the FDA and potential commercialization of dalbavancin for treatment of acute bacterial skin and skin structure infections (ABSSSI)."

2012 Highlights and Recent Events

Our significant accomplishments include the following:

  • Completed enrollment and closed our two Phase 3 clinical trials of dalbavancin, DISCOVER 1 and DISCOVER 2. Both studies met their primary and secondary endpoints, based on preliminary top-line data.
  • Received Qualified Infectious Disease Product (QIDP) designation for dalbavancin from the FDA, which provides Durata priority review by the FDA, eligibility for "fast-track" status, and extension of statutory exclusivity periods for an additional five years upon FDA approval of the product for the treatment of ABSSSI.
  • Completed our initial public offering, resulting in approximately $71.3 million of net proceeds.
  • Entered into a $20.0 million debt facility on March 5, 2013 with Oxford Finance LLC. Net proceeds are expected to be received by the end of March 2013 and used for working capital purposes.

Financial results for the year ended December 31, 2012

As of December 31, 2012, we had cash and cash equivalents plus short-term investments of $45.3 million, compared to $11.5 million at December 31, 2011.

Net loss for the year ended December 31, 2012 (the "2012 Year") was $62.5 million, compared to a net loss of $33.0 million for the year ended December 31, 2011 (the "2011 Year").

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs